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ABSTRACT
Pre-treatment serum levels of sCD163 were measured in a cohort of 236 suspected tuberculosis (TB)
cases from Guinea-Bissau, with a median follow-up period of 3.3 years (range 0–6.4 years). In 113 cases,
the diagnosis of TB was verified by positive sputum microscopy and ⁄ or culture. Among the verified TB
cases, a decreased survival rate was found in 27 patients with sCD163 levels above the upper reference
limit (3.95 lg ⁄mL). The difference in survival was significant during TB treatment (log rank, p < 0.02)
and after long-term follow-up (log rank, p < 0.001). The decrease in survival rate during TB treatment
remained significant in a multivariate Cox model controlling for human immunodeficiency virus (HIV)
status, age and gender, with a mortality increase of 1.19 (95% CI, 1.04–1.36) per lg of sCD163, and a
hazard ratio (HR) for sCD163 levels above the upper reference limit of 4.18 (95% CI, 1.06–16.4). The
difference was not significant after excluding patients with concomitant HIV-1 and HIV-2 infection in
Kaplan–Meier analyses (log rank, p 0.11). In contrast, the difference in survival remained significant in
Kaplan–Meier analyses after long-term follow-up, even after excluding patients with concomitant HIV-1
and HIV-2 infection (log rank, p 0.002). In the Cox model, the mortality increase per lg of sCD163 was
1.27 (95% CI, 1.14–1.40), with an HR for elevated sCD163 levels of 2.85 (95% CI, 1.44–5.63). The HRs for
concomitant HIV-1 and HIV-2 infection were 6.92 (95% CI, 3.28–14.58) and 2.48 (95% CI, 1.09–5.67),
respectively. Thus, sCD163 levels appeared to be an independent predictor of survival in verified TB
patients.
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INTRODUCTION
Tuberculosis (TB) remains a major cause of
morbidity and mortality in resource-poor set-
tings, despite the existence of effective treatment
regimens and global efforts to control disease
spread. Approximately one-third of the global
population is infected with Mycobacterium tuber-
culosis, and there are > 8 million new cases of
active TB and almost 2 million deaths annually
[1]. The impact of TB has been augmented by
the advent of human immunodeficiency virus
(HIV) and the emergence of drug-resistant
strains of M. tuberculosis. The countries most
affected clearly require simple and inexpensive
markers of disease progression and ⁄ or treatment
efficacy.
CD163 belongs to the scavenger receptor
cysteine-rich domain family. It is expressed exclu-
sively on monocytes and macrophages, and is
the endocytic receptor for haptoglobin–haemo-
globin complexes [2]. Soluble CD163 (sCD163) is
shed from macrophages by a protease-mediated
release mechanism in response to inflammatory
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stimuli [3], and may modulate the inflammatory
response [4,5]. The clinical implications of sCD163
in diseases involving the monocyte–macrophage
system are being investigated currently [6]. At
present, it seems clear that both proliferation [7–9]
and inflammatory activation of macrophages
[10,11] result in increased sCD163 levels. Elevated
levels have been found in patients with sepsis
[8,9], and sCD163 levels predict survival in
patients with pneumococcal bacteraemia (H. J.
Møller, personal communication). In addition,
patients infected with the macrophage-tropic
protozoan Leishmania have increased sCD163
levels [9]. As macrophages and monocytes play
a pivotal role in the progression of TB, the aim of
the present study was to investigate whether
sCD163 serum levels are associated with mortal-
ity in verified TB patients.
MATERIALS AND METHODS
Patients
Patients from four suburban areas in Bissau, the capital of
Guinea-Bissau in West Africa, were investigated and have
been followed demographically for several years. In 1996, a TB
surveillance system was established in Bissau in collaboration
with the national referral hospital for lung diseases, Hospital
Raoul Follereau [12]. Patients presenting either at the two local
health centres, or directly at the referral hospital, with
symptoms compatible with active TB were referred by the
hospital for possible inclusion in the study. Inclusion criteria
were age ‡ 15 years and the presence of at least one of the
following, otherwise unexplained, symptoms or signs: persist-
ent cough (> 1 month) without improvement following anti-
biotic treatment; constant or periodic fever (> 1 month);
weight loss; dyspnoea; haemoptysis; night sweats; or lymph-
adenopathy. Patients were investigated with a chest X-ray and
with direct microscopy and culture of sputum. Blood was
screened for HIV using the Capillus HIV-1 ⁄HIV-2 kit
(Cambridge Diagnostics, Galway, Ireland) and the Enzygnost
Anti-HIV 1+2 Plus kit (Behring Diagnostics, Marburg,
Germany). Pre-treatment serum samples were taken at the
time of inclusion in the study.
Based on the findings, patients were divided into three
diagnostic groups (Table 1): (1) verified TB, defined as patients
who were positive for acid-fast bacilli following direct micro-
scopy of sputum, and ⁄ or positive for M. tuberculosis in sputum
culture; (2) presumed TB, defined as patients who were
negative for acid-fast bacilli following direct microscopy and
culture, but who had signs, symptoms and X-ray changes
compatible with active intrathoracic TB—these patients were
treated initially with antibiotics and were then re-evaluated
clinically and with chest X-ray, followed by a presumption of
TB and treatment if there was no improvement; and (3) non-TB
disease, defined as patients who were diagnosed as having
disease other than active intrathoracic TB. Verified and
presumed TB patients were treated according to a regimen
established by the national TB programme (see below), and all
patients included in the study were followed with respect to
mortality until January 2003. In total, 236 patients were
enrolled in the study (128 males and 108 females). The TB
surveillance study was approved by the Ministry of Public
Health in Guinea-Bissau and the Central Ethical Committee of
Denmark.
TB treatment
The TB treatment regimen consisted of directly observed
daily treatment with ethambutol, isoniazid, rifampicin and
pyrazinamide for a period of 4 months, followed by self-
administered treatment for a further 4 months with isoniazid
and ethambutol, collected twice-monthly at the local health
centres. HIV-positive and HIV-negative patients received
identical treatment. All patients received daily doses of
multivitamins and vitamin B complex. Adherence was
verified by counting tablets and an isoniazid urine test after
2, 5 and 8 months. More than 85% of the patients completed
treatment for a 6-month period. Patients were investigated
clinically and with sputum smear microscopy following
treatment for 8 months. No patient yielded a positive sputum
result at this time, and all survivors were thus considered to
be cured of TB.
Soluble CD163 serum levels
Adequate amounts of serum were available from all 236
patients included in the study. Duplicate measurements of
sCD163 were performed retrospectively on frozen pre-treat-
ment serum samples by ELISA as described previously [13].
Control samples and standards of purified CD163 were
co-analysed in each run.
Table 1. Cohort baseline character-
istics used for survival analysis,
with the data divided into two
groups according to sCD163 levels
All cases
sCD163 < 3.95 lg ⁄mL
(n = 189; 76 deaths)
sCD163 > 3.95 lg ⁄mL
(n = 47; 27 deaths)
No. of cases
(total n = 236)
No. of deaths
(total n = 103)
Age, years (median) 39.0 35.0
Male 104 (42 deaths) 24 (15 deaths) 128 57
Female 85 (34 deaths) 23 (12 deaths) 108 46
TB status
Verified TB 86 (24 deaths) 27 (16 deaths) 113 40
Presumed TB 51 (31 deaths) 12 (6 deaths) 63 37
Non-TB disease 52 (21 deaths) 8 (5 deaths) 60 26
HIV status
HIV-1a 25 (23 deaths) 15 (12 deaths) 40 35
HIV-2 48 (26 deaths) 11 (8 deaths) 59 34
HIV-negative 116 (27 deaths) 21 (7 deaths) 137 34
aIncludes patients with a dual infection.
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Statistics
Comparison between groups was performed using the Mann–
Whitney U-test. Comparison of survival rates in groups
according to sCD163 levels was performed by Kaplan–Meier
analysis following stratification according to diagnostic group
(verified TB cases, presumed TB, and non-TB disease). Survi-
val analyses for patients with verified TB were controlled for
HIV status. Differences between Kaplan–Meier curves were
evaluated by the log-rank test. The association between
sCD163 levels and mortality in verified TB cases was assessed
by a Cox regression analysis, with adjustment for other known
risk-factors (age, gender and HIV status) [12,14]. Analysis
of survival during treatment was undertaken from the time of
inclusion to the end of the treatment period, or the first of the
following events: death, disruption of treatment following the
outbreak of war in Guinea-Bissau (6 June 1998) [15], or
abandonment of treatment or lost to follow-up. Multivariate
long-term survival analysis was performed from the time of
inclusion until January 2003 or the first of the following events:
death or lost to follow-up. To evaluate survival rates in verified
TB cases without the potential confounder of a concomitant
HIV infection, Kaplan–Meier analyses excluding all patients
with HIV-1, HIV-2 or dual infection were performed. In the
Cox model, patients with dual infection were included as HIV-
1-positive, as they have been shown to have a similar risk and
severity of TB disease [14]. In the absence of an appropriate
age-, sex- and race-matched control group, an upper reference
limit of 3.95 lg ⁄mL, identified in a previous study of sCD163
[8], was chosen as the dividing parameter for the statistical
analysis. All statistical analyses were performed using SPSS v.
10 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Influence of TB and HIV status on sCD163
levels
A trend (p 0.06) towards elevated sCD163 levels
was observed in verified TB cases (n = 113;
median 2.50 lg ⁄mL) compared with individuals
with non-TB disease (n = 60; median 1.76 lg ⁄mL).
The difference was significant (p 0.02) in patients
positive for acid-fast bacilli following direct micro-
scopy of sputum (n = 82; median 2.70 lg ⁄mL).
No significant differences in sCD163 levels among
presumed TB patients (n = 63; median
2.34 lg ⁄mL) or TB patients negative following
direct microscopy who were culture-positive
(n = 33; median 2.09 lg ⁄mL) were observed in
comparison with TB-negative individuals. The
highest levels were found in verified TB cases
with concomitant HIV-1 infection (n = 19; median
3.11 lg ⁄mL); these patients had significantly
(p 0.02) higher levels than HIV-negative verified
TB patients (n = 68; median 2.34 lg ⁄mL). HIV-1-
and HIV-2-positive patients were distributed uni-
formly among the groups; most notably, 16.8% of
verified TB cases and 15.6% of patients with non-
TB disease were HIV-1-positive.
Predictive value of sCD163 for mortality during
treatment
Mortality during treatment was evaluated in both
a univariate and a multivariate Cox regression
model, since the latter may be of limited value
with few events. The median follow-up period
was 7.3 months (range 0.2–10.5 months). Of 113
verified TB patients, nine died during treatment,
29 were censored at the time of civil war, and 18
were censored at the time when treatment was
abandoned or they were lost to follow-up. Five
(56%) of the nine patients who died during
treatment, and 23 (74%) of the 31 patients who
died after completion of treatment, were HIV-1-
or HIV-2-positive. In univariate analysis, an
increased hazard ratio (HR) was found per lg of
sCD163 of 1.18 (95% CI, 1.05–1.32), with an HR of
4.32 (95% CI, 1.2–16.1) for sCD163 levels above
the upper reference limit. In the multivariate
model controlling for HIV status, age and gender,
only sCD163 remained significant (p 0.01), with
an increased HR per lg of sCD163 of 1.19 (95%
CI, 1.04–1.36) and an HR of 4.18 (95% CI, 1.06–
16.4) for sCD163 levels above the upper reference
limit. Thus, elevated sCD163 levels were associ-
ated with increased mortality during the 8-month
treatment period in verified TB cases.
Value of sCD163 as an independent predictor of
long-term mortality
Long-term mortality, defined as mortality
between the time of inclusion and January 2003,
was evaluated using the multivariate Cox model,
controlling for HIV status, age and gender. The
median follow-up period was 3.5 years (range 0–
6.4 years). Of 113 verified TB patients, 40 died and
25 were lost to follow-up. The long-term mortality
increase per lg of sCD163 was 1.27 (95% CI,
1.14–1.40), with an HR of 2.85 (95% CI, 1.44–5.63)
for sCD163 levels above the upper reference limit.
HIV status remained a significant risk-factor in
the model, with HRs of concomitant infection of
6.92 for HIV-1 (95% CI, 3.28–14.58) and 2.48 for
HIV-2 (95% CI, 1.09–5.67) for verified TB cases.
There was no significant relationship with age or
gender in this model.
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Association between high sCD163 levels and
increased mortality
Kaplan–Meier survival analysis showed that veri-
fied TB cases with sCD163 levels > 3.95 lg ⁄mL
were associated with increased mortality during
treatment, as well as after long-term follow-up,
compared with verified TB cases with sCD163
levels < 3.95 lg ⁄mL (Fig. 1a,b n = 113; log rank,
p 0.017 and p < 0.001, respectively). When HIV
status was controlled for, the difference in long-
term survival remained significant in both
HIV-negative (Fig. 1c; n = 68; log rank, p 0.002)
and HIV-1- and ⁄ or HIV-2-positive individuals
(Fig. 1d; n = 45; log rank, p 0.02); however, the
difference was not significant during treatment
(log rank, p 0.11 and p 0.13, respectively). There
was no significant effect of sCD163 levels on
survival for patients with presumed TB (n = 63;
log rank, p 0.28) or patients with non-TB disease
(n = 60; log rank, p 0.20).
DISCUSSION
The results of this study indicated that levels of
sCD163 predict mortality during treatment, as
well as long-term mortality, in verified cases of
TB. There was a significant association between
elevated sCD163 levels and mortality during
treatment in both Kaplan–Meier (Fig. 1a) and
TB-treatment follow-up in months
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Fig. 1. Kaplan–Meier plots showing survival during treatment and long-term survival of verified cases of tuberculosis.
Vertical lines indicate censoring. The upper bold line indicates patients with sCD163 levels below the upper reference limit
of 3.95 lg ⁄mL, and the lower line indicates levels above the upper reference limit of 3.95 lg ⁄mL. (a) Overall survival
during treatment in verified TB cases (n = 113; 27 cases > 3.95 lg ⁄mL; p 0.017). (b) Overall long-term survival in verified
TB cases (n = 113; 27 cases > 3.95 lg ⁄mL; p < 0.001). (c) Long-term survival in HIV-negative verified TB cases (n = 68, 14
cases > 3.95 lg ⁄mL; p 0.002). (d) Long-term survival in verified TB cases with concomitant HIV-1 and ⁄or HIV-2 infection
(n = 45; 13 cases > 3.95 lg ⁄mL; p 0.02).
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univariate Cox regression analyses. The decrease
in survival rate during TB treatment remained
significant when controlling for HIV status in a
multivariate Cox regression model, but not when
completely excluding patients with concomitant
HIV-1 and HIV-2 infection in Kaplan–Meier
analysis. However, because of the relatively few
events occurring during the treatment period,
these results should be interpreted with caution.
The association between sCD163 levels and long-
term mortality remained significant for both TB
patients and TB patients co-infected with HIV
(Fig. 1b,d). Among verified TB cases, significantly
higher sCD163 levels were found in HIV-1-posit-
ive than in HIV-negative individuals. Thus, both
TB and HIV status influenced sCD163 levels,
although their relative contributions to the
observed increase remain unclear. However, the
inherent limitations of the study design and the
lack of data for standard markers of disease
progression (e.g., CD4 cell counts and HIV virus
loads) do not allow conclusions to be reached
concerning possible associations between sCD163
levels and mortality in HIV disease.
The finding that patients with verified TB and
HIV-1 infection had the highest sCD163 levels is
in agreement with previous observations [14] that
the severity of TB disease is augmented by
concomitant HIV-1 disease (Fig. 1d). Most nota-
bly, the observation that sCD163 levels predict
mortality, even when HIV-1- and HIV-2-infected
patients are excluded, suggests that sCD163 may
be a sensitive marker for the severity of TB
disease (Fig. 1c).
Considering the natural course of TB, it might
be expected that most deaths related directly to
TB disease would occur during the first year of
follow-up. In accordance with this hypothesis,
elevated sCD163 levels were found to be associ-
ated with increased mortality during the 8-month
treatment period. Surprisingly, the long-term
survival analyses showed that substantial mortal-
ity occurred after the first year (Fig. 1b). Whether
the predictive value of sCD163 for long-term
survival reflects treatment failure, reactivation of
latent TB, development of resistant bacteria, or a
general susceptibility to disease, remains to be
clarified. The present data suggest that sCD163
may be a sensitive marker for TB disease; how-
ever, it is possible that elevated levels may also
reflect other conditions that carry an increased
risk of mortality. A biological understanding of
these observations requires further investigation,
but it could be speculated that elevated levels of
sCD163 may parallel an increased mobilisation
and inflammatory activation of macrophages and
monocytes that reflects the severity of TB disease.
The putative function of sCD163 as a modulator
of the inflammatory response is in agreement
with our findings.
In conclusion, the results of this study demon-
strate that both TB and HIV status influence
sCD163 levels, and that high levels of sCD163 are
associated with increased mortality in verified
cases of TB. The findings suggest that measure-
ment of sCD163 levels may be a useful prognostic
tool in TB disease. However, further prospective
studies are needed to confirm the results and to
evaluate the effect of anti-tuberculosis drugs on
sCD163 levels in order to determine whether such
measurements can be used to monitor treatment
efficacy.
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